KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Operating Income (2016 - 2025)

AbbVie (ABBV) has disclosed Operating Income for 14 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income rose 404.97% to $4.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $15.1 billion, a 64.99% increase, with the full-year FY2025 number at $15.1 billion, up 64.99% from a year prior.
  • Operating Income was $4.5 billion for Q4 2025 at AbbVie, up from $1.9 billion in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $5.5 billion in Q4 2022 to a low of -$1.5 billion in Q4 2024.
  • A 5-year average of $3.7 billion and a median of $4.1 billion in 2021 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: surged 490.56% in 2021, then plummeted 146.64% in 2024.
  • AbbVie's Operating Income stood at $5.1 billion in 2021, then grew by 8.44% to $5.5 billion in 2022, then crashed by 41.93% to $3.2 billion in 2023, then tumbled by 146.64% to -$1.5 billion in 2024, then skyrocketed by 404.97% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Operating Income are $4.5 billion (Q4 2025), $1.9 billion (Q3 2025), and $4.9 billion (Q2 2025).